title: [Compliance to therapy with Dapoxetine in patients affected by Premature Ejaculation].
abstract: BACKGROUND
  Premature ejaculation (PE) is a sexual dysfunction with high prevalence. According to some reports, it is present in about 20-30% of the male population. Since 2009 PE has been treated with a novel inhibitor of serotonin re-uptake, Dapoxetine, which has been reported to be specifically active for PE.
  
  
  METHODS
  59 patients have been selected among the patients affected by PE observed at the outpatient department of Urology and Andrology of the "Paolo Giaccone" University Policlinic Hospital of Palermo. Diagnosis was confirmed unequivocally in all patients, who were suitable for drug treatment and accepted to participate in the study. They were divided in 2 groups: one receiving Dapoxetine (41 patients), another (18 patients) receiving Citalopram. Patients were followed up by telephone at monthly intervals, in order to compare compliance, efficacy and side effects:
  
  
  RESULTS
  Compliance to treatment was obtained in 56% of patients treated with Dapoxetine and in 61% of those treated with Citalopram. In the Dapoxetine group side effects were reported in 14.6% versus 38.4% in the Citalopram group. Benefit from the treatment was reported in 82% and 69.2%, respectively.
authors.affiliation: AOUP Paolo Giaccone, Dipartimento Materno-Infantile, Andrologia e Urologia, UOC Urologia, Palermo, Italy. uropa@unipa.it
authors.forename: Carlo
authors.initials: C
authors.lastname: Pavone
authors.forename: Cristina
authors.initials: C
authors.lastname: Scalici Gesolfo
authors.forename: Daniela
authors.initials: D
authors.lastname: Abbadessa
authors.forename: Giovanna
authors.initials: G
authors.lastname: Scaduto
authors.forename: Giovanni
authors.initials: G
authors.lastname: Caruana
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Siracusa
authors.forename: Giuseppa
authors.initials: G
authors.lastname: Gambino
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Marguglio
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001596:Benzylamines / Q000009:adverse effects / Q000627:therapeutic use*; D015283:Citalopram / Q000009:adverse effects / Q000627:therapeutic use; D015897:Comorbidity; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D008019:Life Style; D008297:Male; D055118:Medication Adherence; D008875:Middle Aged; D008881:Migraine Disorders / Q000139:chemically induced; D009281:Naphthalenes / Q000009:adverse effects / Q000627:therapeutic use*; D009422:Nervous System Diseases / Q000139:chemically induced; D010342:Patient Acceptance of Health Care; D061686:Premature Ejaculation / Q000188:drug therapy* / Q000453:epidemiology; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011795:Surveys and Questionnaires; D055815:Young Adult
chemical_list: D001596:Benzylamines; D015283:Citalopram; D009281:Naphthalenes; D017367:Selective Serotonin Reuptake Inhibitors; C080598:dapoxetine